avexitide

Peptide

Partialsignal

Evidence outlook · lead readout

LUCIDITY (NCT06747468) · Post-Bariatric Hypoglycemia

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

LUCIDITY (NCT06747468): LUCIDITY was a randomized, double-blind, placebo-controlled Phase 3 in post-bariatric hypoglycemia. Its primary endpoint, the rate of clinically significant hypoglycemic events, is a clinical outcome and was met according to the company's topline release. The sources read give no power calculation, so the grade is moderate.

Company guidance: regulatory filing expected by the end of 2026 (Amylyx Pharmaceuticals, Inc., 5 Nov 2026). “We plan to submit a New Drug Application, or NDA, for avexitide to the FDA by the end of 2026.” Source ↗

Company guidance: regulatory filing expected by end of 2026 (NCT06747468; Amylyx Pharmaceuticals, Inc., 5 Nov 2026). “Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Post-Bariatric Hypoglycemia
Phase 2 (2)
Post-Bariatric Hypoglycemia
NCT02771574 · Tracey McLaughlin
2016-05 – 2017-06 · Post Bariatric Hypoglycemia
What this study did
Other / comorbidity
NCT04652479 · Dr. Tracey McLaughlin, MD
2021-06-21 – 2022-06-30 · Acquired Hyperinsulinemic Hypoglycemia
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 August 2026Topline resultLUCIDITY Phase 3 (NCT06747468) meets primary endpoint
Amylyx Pharmaceuticals, Inc. · Source ↗